Information Provided By: 
Fly News Breaks for May 22, 2017
RDUS, AMGN
May 22, 2017 | 08:27 EDT
After Amgen (AMGN) and UCB reported an "imbalance of positively adjudicated serious cardiovascular adverse events" in its Phase 3 study of Evenity, Leerink analyst Geoffrey Porges believes the product now has only a 50/50 probability of coming to market at all. The analyst lowered his price target for Amgen shares to $159 from $160 and keeps a Market Perform rating on the name. Radius Health (RDUS), which has a drug that would compete with Evenity, is trading up 16% to $40.58 in the premarket.
News For AMGN;RDUS From the Last 2 Days
There are no results for your query AMGN;RDUS
